BREXAFEMME — Class I drug recall D-0042-2024
Completed recall by Scynexis, Inc., reported 2023-10-18, distributed nationwide. Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance
| Recall number | D-0042-2024 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Completed |
| Voluntary or mandated | Voluntary |
| Recalling firm | Scynexis, Inc., Jersey City, NJ, United States |
| Recall initiated | 2023-09-25 |
| Classified | 2023-10-06 |
| Reported by FDA | 2023-10-18 |
| Distributed | Nationwide (US) |
| Quantity | 17,376 |
| NDC | 75788-0115-04 |
| Lot numbers | LF21000008, LF22000051 |
| Expiration dates | 2023-11-30, 2025-11-30 |
Product
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Reason for recall
Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0042-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.